Bcl-xL antibody | knockout validation

Bcl-xL antibody | knockout validation | Cell Signaling 2764

This is a knockout-validated antibody summary, based on the publication "Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

[enlarge]

Bcl-xL antibody | knockout validation | Cell Signaling 2764 figure 1

Figure 1. CRISPR-mediated deletion of Bcl-xL in lung adenocarcinoma cell lines. From [1].

Antibody information

Rabbit monoclonal IgG

Company: Cell Signaling

Antibody: Bcl-xL

Catalog number: 2764

Summary: Rabbit monoclonal antibody against a synthetic peptide corresponding to residues surrounding Asp61 of human Bcl-xL. Reacts with human, mouse, rat, and monkey. Suitable for western blot, immunoprecipitation, immunohistochemistry (paraffin), immunofluorescence/immunocytochemistry and flow cytometry (fixed/permeabilized).

Validation Method

Western blot

Sample

Control and Bcl-xL knockout lung adenocarcinoma cells.

Primary incubation

1:1,000 dilution.

References

Sanchez Rivera F, Ryan J, Soto Feliciano Y, Clare Beytagh M, Xuan L, Feldser D, et al. Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration. Proc Natl Acad Sci U S A. 2021;118: pubmed publisher

contribute

If you are aware of any publication with knockout studies validating a monoclonal or recombinant antibody, either purchased from a supplier or developed by the author(s), please notify us through feedback.